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nomic method to rapidly identify HLA-DRB1*0401 individuals in the
research laboratory. The ﬁrst step was to screen peripheral blood
mononuclear cells (PBMC) with anti-HLA-DR4 antibody (0222HA)
that we identiﬁed to be speciﬁc for HLA-DR4. PBMC from 4 out of
33 healthy blood donors were stained to be positive for HLA-DR4 by
FACS analysis. The second step was to test whether HLA-DR4
positive PBMC identiﬁed by the antibody 0222HA can present In-
ﬂuenza HA peptide (PKYVKQNTLKLAT) to HLA-DRB1*0401
restricted T cell hybridoma generated in HLA-DR4 transgenic mice.
Using this assay we demonstrated that 3 out of 4 HLA-DR4 positive
PBMC could present HA peptide to T cell hybridoma as efﬁciently as
the control EBV-transformed B cells (Priess) that express HLA-
DRB1*0401, whereas the EBV-transformed B-cells (EBV26) that
express HLA-DRB1*0431 or PBMC from 5 randomly chosen donors
that were HLA-DR4 negative were unable to present HA antigen to
T cells. The third step was to subtype HLA-DR4 at a high resolution
using PCR-based sequence-speciﬁc primers. This assay conﬁrmed
that these 3 donors whose PBMC could present HA peptide to T cells
were HLA-DRB*0401 and 1 donor whose PBMC were unable to
present HA antigen was HLA-DRB1*0436. Taken together, we con-
clude that this combinational HLA-DR4 typing method was speciﬁc,
rapid, relatively cheap and suitable for research laboratories. Our
future studies will test if antigen-speciﬁc CD4 T cells generated from
HLA-DRB1*0401 individuals can be used to identify therapeutic
antigens following bone marrow transplantation.
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CORD BLOOD NATURAL KILLER T (NKT) CELLS
Dalle, J.-H.1, Menezes, J.1, Champagne, M.2, Michel, D.1 1. Labora-
tory of Immunovirology, Hoˆpital Sainte-Justine, Montreal, QC, Can-
ada; 2. Departement of Hematology-Oncology, Hoˆpital Sainte-Justine,
Montreal, QC, Canada.
In cord blood (CB) transplantation, the GVHD rate is low
despite HLA-disparity, and the rate of leukemia relapse is identical
to that of bone marrow transplantation. In a murine model, NKT
cells demonstrate a graft-versus-leukemia activity without causing
GVHD. We therefore investigated CB-natural killer-T (NKT)
cells, by comparing their phenotypic properties with those of adult
blood (AB)-NKT cells. Mononuclear cells from 12 CB and 12 AB
samples were analyzed by ﬂow cytometry after triple-staining with
MoAb against CD56, CD3 and a third MoAb. NKT cells were
deﬁned as CD3CD56 cells. The percentage of NKT cells was
5-fold lower in CB than in AB (0.35 vs 1.56%, P  0.01). CD28,
a marker of naive T-cells, was more frequently expressed on CB-
NKT cells than on AB-NKT cells (96 vs 85%, P  0.02). The
percentage of CD11c-(integrin aX subunit) positive NKT cells was
higher in CB than in AB (85 vs 45 %; P  0.001 in both). The
percentage of NKT cells expressing intracellular perforin and
granzyme B, and surface FAS-L was higher in CB than in AB (83
vs 60 %; 88 vs 51% and 71 vs 45%; P  0.04). No difference
between CB and AB-NKT cells was noted for the expression of
CD2, CD57, L-selectin, TRAIL, FAS-L, NKG2A, NKB1, and
HLA-DR. Because of their scarcity, CB-NKT cells can not be
functionally studied without prior expansion. Taken together, our
results show that CB-NKT cells are very scarce in CB and that
their phenotype resembles that of AB-NKT cells, except that a
signiﬁcantly higher percentage of CB-NKT cells express cytotox-
icity-associated proteins.
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TEN ALLELE HIGH-RESOLUTION DNA TYPING HAS A DIRECT IMPACT
ON THE DISEASE FREE SURVIVAL (DFS) IN PEDIATRIC RECIPIENTS OF
T-CELL DEPLETED (TCD) UNRELATED DONOR (URD) HEMATOPOIETIC
STEM CELL TRANSPLANT (HCT)
Prasad, V.K.1, Selvakumar, A.2, Dastigir, H.1, Boulad, F.1, Small,
T.N.1, Prockop, S.1, Dupont, B.2, O’Reilly, R.J.1, Kernan, N.A.1 1.
Pediatric BMT Service, Memorial Sloan Kettering Cancer Center, New
York, NY; 2. Human Immunogenetics, Memorial Sloan Kettering Can-
cer Center, New York, NY.
We have shown that 1) many URD pairs matched for HLA-A,
-B, and -DRB1 alleles are disparate for one or more -C and -DQB1
alleles; and 2) matching for three loci (HLA-A, -B, and -DRB1) by
molecular as opposed to serologic typing has a direct impact on the
outcome of URD HSCT. In this study we looked at the impact of
the molecular matching at HLA-C and -DQB1 in addition to
HLA-A, -B, and -DRB1 on the outcome of URD TCD HCT.
HLA typing for all ﬁve loci was available on 47 consecutive patients
18 yrs with acute leukemia (n  40); MDS (n  5) or NHL (n 
2) transplanted between 1994 and 2002. The median follow up was
19.8 (range 1 to 108) months. BM was TCD by soybean lectin
agglutination plus E-rosette (n  41) or T10B9 MoAb plus Com-
plement (n  5). One pt received TCD PBSC (Isolex plus E-ro-
sette). Pts received a myeloablative regimen including TBI in 44
pts. Using sequence speciﬁc oligonucleotide probe (SSOP) typing
and/or DNA sequencing, 26 pairs were HLA-A, -B and -DRB1 6/6
matched. Additional typing showed 73% of the 6/6 matched pairs
were also identical at -C and -DQB1 (10/10 matched) while the
remainder was disparate for one (n  4), or two (n  3) -C or
-DQB1 alleles. The DFS in HLA 6/6 (n  26) and 10/10 (n  19)
groups was 52% and 58%, respectively (pNS). DFS in the good
risk 6/6 (n  18) and 10/10 (n  12) matched pairs was 71% and
83% (p  NS), respectively. Of the remaining 28 donor-recipient
pairs, matching was 9/10 (N 10); 8/10 (N 9); 7/10 (N 6) and
6/10 (N  3). DFS in the 8/10 and 9/10 matched pairs was 43%
while the DFS in 6/10 and 7/10 matched pts was 11% (p  .05).
DFS in 4/6 and 5/6 patients without an HLA-C and -DQB1
disparity was higher (57%) than those with HLA -C and/or
-DQB1 disparity (21%). The difference did not reach statistical
signiﬁcance due to small numbers. All 10/10 patients engrafted.
Graft rejection was seen in 5% of 8-10/10 pt. Grade III/IV
AGVHD was seen in 0% of 10/10 and 10% of 8-9/10 pts. In
conclusion, in pediatric recipients of TCD-HCT matched for
HLA -A, -B and -DRB1 by high resolution typing, disparities
detected by high resolution typing of HLA-C and -DQB1 does not
impact outcome. Good risk pts who are HLA matched at 6/6 or
10/10 have a low incidence of graft failure and GVHD and have
excellent DFS (71% and 83%, respectively). In contrast, the DFS
in 5/6 and 4/6 pts with HLA -C and -DQB1 disparities is im-
pacted, such that the DFS of HLA 8-9/10 matched pairs is signif-
icantly higher than that of HLA 6-7/10 pairs (43% vs.11%, p 
0.05).
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CHIMERISM AND TOLERANCE POST IN UTERO TRANSPLANTATION
WITH ONTOGENICALLY DIFFERENT SOURCES OF STEM CELLS
Carrier, E., Moustafa, M.E., Srivastava, A.S., Nedelcu, E.E.S.M.,
Minev, B. Rebecca and John Moores UCSD Cancer Center, School of
Medicine, La Jolla, CA.
Prenatal transplantation (IUT) is a promising strategy for the
early treatment of hemoglobinopathies and genetic disorders. We
have previously demonstrated that fetal liver cells injected prena-
tally induced tolerance, while cytokine stimulated peripheral blood
stem cells induce allosensitization. In order to this hypothesis, we
have transplanted Balb/c fetuses (H-2d) at day 13-14 of gestation
with 5x103 129 embryonic, fetal liver and bone marrow stem cells
from C57BL/6J mice (H-2b) by intra-peritoneal injection. Trans-
planted mice received boosts (transplants without conditioning)
nine month after birth, by intravenous injection of 40x106 of the
corresponding cells. The pre-boost donor chimerism detected by
highly sensitive (0.01%) semi-quantitative PCR assay demon-
strated 0.1-3% of donor cells at 6 weeks and 0.2% at 9 months.
Our hypothesis is that prenatally induced allosensitization was
responsible for this decrease in donor chimerism. This was sup-
ported by the observation that cytotoxicity assay showed shift
towards immunity and the fact that postnatal injections of high
dose donor cells resulted in low level donor chimerism. We con-
clude that the low level of donor chimerism obtained after prenatal
transplantation may lead to allosensitization. The cell dose re-
quired for prenatal tolerance induction may be much higher than
that used in this experiment and relevant experiments to test this
hypothesis are in progress. Ongoing studies are pending to delin-
eate differences between embryonic, fetal and adult sources of stem
cells in chimerism and tolerance induction and will be presented.
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